- SQI Diagnostics (SQD) has received Health Canada Interim Order authorization for its Rapid Acute Lung Injury Diagnostic (RALI-Dx) IL-6 Severity Triage Test
- RALI-Dx is the first interleukin-6 (IL-6) diagnostic test approved in Canada
- SQI CEO Andrew Morris sat down with Daniella Atkinson to discuss the news
- SQI Diagnostics Inc is a Canada-based company engaged in developing and commercializing technologies & products for multiplexing diagnostics
- SQI Diagnostics opened trading at C$0.105
SQI Diagnostics (SQD) has received Health Canada Interim Order authorization for its Rapid Acute Lung Injury Diagnostic (RALI-Dx) IL-6 Severity Triage Test.
RALI-Dx is the first interleukin-6 (IL-6) diagnostic test approved in Canada, and its turnaround time of less than an hour is developed to fill an important and unmet public health need.
SQI Diagnostics CEO Andrew Morris sat down with Daniella Atkinson to discuss the news.
“COVID continues to strain our health care system, continues to spawn new variants and continues to be a challenge as new waves continue to form,” said Andrew Morris, President and CEO of SQI Diagnostics.
“We believe RALI-Dx will be an important tool in the hands of Emergency Room doctors to help raise survival rates for the most seriously ill COVID patients while also improving the efficiency and efficacy of hospital care. We also hope to investigate its potential use in other severe respiratory health conditions.”
The Severity Triage test is intended to play a vital role in clarifying COVID-19 patient risk. By testing for the presence of the key bio-marker IL-6, RALI-Dx helps identify which patients are most at risk of a severe inflammatory response from cytokine storms, which is associated with the worst patient outcomes.
SQI Diagnostics is a Canada-based company engaged in developing and commercializing technologies & products for multiplexing diagnostics.
SQI Diagnostics Inc. (SQD) opened trading at C$0.105.